Federal court Zantac lawsuits were dismissed after ... and independent laboratories shows that one ranitidine 300 mg tablet can contain tens of thousands of nanograms (ng) of NDMA, greatly ...
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
GSK plc (LSE/NYSE: GSK) today announced that it has reached agreements with 10 plaintiff firms who together represent 93% (approximately 80,000) of the Zantac (ranitidine) state court product ...
The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.
GSK gained approval for Zantac (ranitidine) in 1983 and lost its patent protection for the treatment in 1997. Boehringer acquired the U.S. OTC rights for Zantac later in 2006. Sanofi and Pfizer ...
These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company. Under these agreements, GSK will pay up to $2.2 billion to resolve the claims, contingent ...
WJET Erie on MSN2d
Drugmaker to settle nearly 80K Zantac lawsuits for up to $2.2 billionUK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback